博瑞医药近期接受投资者调研时称,公司卡前列素氨丁三醇原料药及制剂、甲磺酸艾立布林原料药及制剂已在国内申报,卡前列素氨丁三醇原料药已在美国申报,甲磺酸艾立布林原料药已在美国、日本、欧洲申报,舒更葡糖钠原料药已在欧洲、韩国通过技术审评,并已在国内及美国申报,地诺孕素原料药及制剂处于稳定性阶段。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.